

## 29th Workshop of the EURORDIS Round Table of Companies

## How to teach an old medicine new tricks The importance of repurposing medicines for patients

## Wednesday, 19 February 2020 (09:00 to 17:30)

The Crowne Plaza – Le Palace, Brussels

## **DRAFT PROGRAMME**

Morning Session Co-Chairs:		
Serge Braun, PharmD, PhD, Scientific director, AFMTelethon		
09.00 - 09.20	Welcome introduction, setting the scene & goals for the day	
	Yann Le Cam, Chief Executive Officer, EURORDIS-Rare Diseases Europe	
09.20–09.40	EU initiatives on timely access to innovative medicines	
	Helen Lee, Administrator, DG Health and Food Safety - European Commission	
	Stakeholders' interests for repurposed medicines:	
why do we need them and why is it difficult to obtain?		
09.50 - 10.05	Professor Marc Dooms, Leuven University Hospitals	
10.05 - 10.20	Ciska Verbaanderd, PhD Student, Anticancer Fund	
10.20 - 10.35	Karine Proulx, Drug and Discovery Alliance Manager, Healx	
10.35 - 11.00	Discussion	
11.00 - 11.30	Coffee break	
The	absence of a regulatory framework is one of the difficulties.	
How can the STAMP initiative help and how does it work?		
11.30 - 11.50	The STAMP proposal/discussion: the framework, how it works, pilots, RepOG	
	César Hernández García, Head of the Department of Medicines for Human Use,	
	AEMPS	
11.55 – 13.00	Facilitated panel discussion + Q&A from audience	
	Panellist representatives:	
	Christelle Bouygues, Regulatory Affairs, European Medicines Agency	
	Sini Eskola, Director, Team Leader Regulatory, Drug development and	
	Manufacturing, EFPIA	
	Beate Stepniewska, Deputy Director General & Head of Regulatory Affairs,	
	Medicines for Europe	
	Professor Ranganath, Royal Liverpool University Hospital, AKU Society Trustee	
13.00 - 14.00	Lunch	
Afternoon Session Co-Chairs:		
Pablo Lapunzina, Scientific Director, CIBERER		
How can we support academics and non-profits in re-purposing medicines?		
Incentives, intelligence, funding, etc.		



14.00 - 14.15	Ferenc Marofka, Policy Officer – Health Research & Innovation at European
	Commission
14.15-14.30	Barbara Goodman, President & COO, Cures Within Reach
14.30 - 15.00	Q&A from audience
15.00 - 15.20	Coffee break
What o	lo you think of this initiative? Initial reactions and discussion
15.20 – 16.20	<ul> <li>3 simultaneous Breakout Sessions, all sessions will address:</li> <li>✓ Initial reactions: given current legal framework, does scientific advice respond to industry's questions when deciding whether or not to repurpose a medicine?</li> </ul>
	<ul> <li>Are relations between champions, regulators and industry clear or are there aspects that require simplifying or alternatives?</li> <li>Pricing of repurposed medicines: how to keep prices reasonable / reactions/concerns/questions from industry</li> </ul>
	<ul> <li>Breakout session 1</li> <li>Moderator: François Houÿez, Treatment Information and Access Director, Health Policy Advisor, EURORDIS-Rare Diseases Europe</li> <li>Rapporteur: Russell Wheeler, LHON Society</li> </ul>
	<ul> <li>Breakout session 2</li> <li>Moderator: Simone Boselli, Public Affairs Director, EURORDIS-Rare Diseases Europe</li> <li>Rapporteur: Vesna Aleksovska, Chair &amp; BoD of the International Gaucher Alliance, BoD of Macedonia National Alliance, Chairman of the association of citizens for rare diseases</li> </ul>
	<ul> <li>Breakout Session 3</li> <li>Moderator: Elizabeth Vroom, Founder &amp; President of the Duchenne Parent Project Netherlands</li> <li>Rapporteur: Leonardo Scapozza, Pharmaceutical Biochemistry/Chemistry, School of Pharmaceutical Sciences, University of Geneva</li> </ul>
International Initiatives	
16.30 - 16.45	Noel Southall, IRDiRC
16.45 - 17.00	Noel Southall, National Centre for Advancing Translational Sciences, NIH
17.00 - 17.20	Discussion
17.20 – 17.30	Toolkit overview: next steps on how to implement what you have heard today Concluding remarks François Houÿez, Treatment Information and Access Director, Health Policy
	Advisor, EURORDIS-Rare Diseases Europe
17.30	Meeting ends